Media Update, page-613

Here you go. MD's AGM presentation (Slide 11, 4 Nov'20) - as per the scale-up plan, capacity should be upto 5.4m devices per Qtr.



What's been a bit unclear is whether above represents all production capacity (HIV, OEM supply, all pipeline items - which use different devices and future versions pending release) or just OEM related supply.

My opinion is that the graph represents total supply, based around blister pack production levels (Galileo, Pascal, new Elion)

In any case, regardless of device type, immediate supply ability shouldn't be an issue considering there has to be several million devices stockpiled since Jan'21 production levels (some of which would be now going to Unitaid HIV order + OEM agreements like AccBio Ab + potential supply for NG Biotech Ab test + other partners/markets being developed)